fashion -WSS

fashion

author：focus 2025-09-30 04:58:28 - browse：1388

Yichuan Cao/Sipa USA via AP Images

Gilead Sciences said Monday that Trodelvy, its “smart-bomb” medicine that combines an antibody with chemotherapy, did not significantly extend the lives of patients with metastatic non-small cell lung cancer when given after a first treatment failed.

The result, from a closely watched study called Evoke-01, will be seen as a disappointment by investors and oncologists alike.

Drugs like Trodelvy, known as antibody drug conjugates, are one of the hottest areas in oncology. The idea is that these medicines combine an antibody, which is triggered when it binds to a protein on a cancer cell, with a “payload” of chemotherapy that poisons the cancer.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： What's changing in Medicare's open enrollment this year?

Wikipedia

WSS

Organ aging and disease risk measured by new blood test

What don’t we know about an Alzheimer’s drug side effect?

Better Therapeutics data on benefit with GLP

Is mRNA technology the right fit for flu shots? Experts aren’t so sure

Bernie Sanders bashes nonprofit hospitals over their tax breaks

Is mRNA technology the right fit for flu shots? Experts aren’t so sure

Wikipedia

fashion

explore

Hepatitis C has a cure — but many Americans still lack access to it

What to do when lifesaving products contribute to climate change

As demand for Covid shots wanes, Moderna seeks its next success

A fraught question for the kids of Alzheimer’s: Is it coming for us?

Hollywood unions extend contract negotiations for actors

Readout LOUD podcast: Merger Mondays, Ozempic panic

Heart attack and stroke risk calculators need revising

Humana CEO Bruce Broussard to step down in 2024

As demand for Covid shots wanes, Moderna seeks its next success

Will the market for weight loss drugs really reach $100 billion?

focus

A fraught question for the kids of Alzheimer’s: Is it coming for us?

European regulators recommend Amylyx's ALS drug be rejected

Pediatric cancer treatments threatened by a new FDA policy

Researchers CRISPR chickens in bid to protect them from bird flu

Is mRNA technology the right fit for flu shots? Experts aren’t so sure

Wellcome Trust names Røttingen as its new CEO

Wikipedia

Wikipedia

hotspot

focus